產品詳情
簡單介紹：
Anti-MBTD1抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-MBTD1抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-MBTD1
Cat. Number:
Anti-MBTD1抗體KL-18710R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
The transcriptional repressing Polycomb-group (PcG) family is a part of a cellular memory system responsible for the stable inheritance of gene activity. PcG proteins assemble into multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. MBTD1 (malignant brain tumor domain containing 1) is a 628 amino acid nuclear protein that belongsAnti-MBTD1抗體 to the PcG family of proteins. Existing as a monomer, MBTD1 undergoes alternative splicing events to produce three isoforms. MBTD1 contains one FCS-type zinc finger and four MBT repeats, and is encoded by a gene that maps to human chromosome 17q21.33. Chromosome 17 comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1.
Also known as:
AA408199; AI194990; FLJ20055; Anti-MBTD1抗體FLJ42067; Hemp; mbt domain containing 1; MBT domain-containing protein 1; mbtd1; MBTD1_HUMAN; MGC126785; RP23-440P13.2; SA49P01.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, .
●
Immunogen: KLH conjugated Anti-MBTD1抗體synthetic peptide derived from human MBTD1.
●
Predicted Molecular Weight: 71kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-MBTD1抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-MBTD1抗體
Optimal working dilutions must be determined by the end user.
